Log in

NASDAQ:ACIUAC Immune Stock Price, Forecast & News

$7.09
-0.20 (-2.74 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.05
Now: $7.09
$7.30
50-Day Range
$6.57
MA: $7.06
$7.74
52-Week Range
$4.07
Now: $7.09
$10.14
Volume29,700 shs
Average Volume67,246 shs
Market Capitalization$479.00 million
P/E RatioN/A
Dividend YieldN/A
Beta0.51
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics, as well as Nestlé Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.
Read More
AC Immune logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACIU
CUSIPN/A
Phone41-21-345-9121

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$111.75 million
Cash Flow$0.64 per share
Book Value$4.06 per share

Profitability

Net Income$45.74 million

Miscellaneous

Employees92
Market Cap$479.00 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.

AC Immune (NASDAQ:ACIU) Frequently Asked Questions

How has AC Immune's stock been impacted by COVID-19 (Coronavirus)?

AC Immune's stock was trading at $5.49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACIU stock has increased by 29.1% and is now trading at $7.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AC Immune?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AC Immune.

When is AC Immune's next earnings date?

AC Immune is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for AC Immune.

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) issued its earnings results on Monday, May, 4th. The company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.07. The business earned $12.83 million during the quarter, compared to analyst estimates of $10.30 million. AC Immune had a negative return on equity of 8.71% and a negative net margin of 52.68%. View AC Immune's earnings history.

What price target have analysts set for ACIU?

1 brokers have issued twelve-month target prices for AC Immune's stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate AC Immune's share price to reach $11.00 in the next year. This suggests a possible upside of 55.1% from the stock's current price. View analysts' price targets for AC Immune.

Has AC Immune been receiving favorable news coverage?

News coverage about ACIU stock has been trending somewhat negative recently, InfoTrie reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AC Immune earned a news sentiment score of -1.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about AC Immune.

Are investors shorting AC Immune?

AC Immune saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 616,200 shares, a drop of 7.6% from the June 15th total of 666,900 shares. Based on an average trading volume of 107,300 shares, the days-to-cover ratio is currently 5.7 days. Approximately 1.6% of the shares of the stock are short sold. View AC Immune's Current Options Chain.

Who are some of AC Immune's key competitors?

What other stocks do shareholders of AC Immune own?

Who are AC Immune's key executives?

AC Immune's management team includes the following people:
  • Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 61)
  • Mr. Joerg Hornstein, Chief Financial Officer (Age 41)
  • Mr. Piergiorgio Donati, Head of Technical Operations & Program Management (Age 48)
  • Dr. Marie Kosco-Vilbois, Chief Scientific Officer (Age 61)
  • Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 48)

When did AC Immune IPO?

(ACIU) raised $55 million in an initial public offering on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $7.09.

How big of a company is AC Immune?

AC Immune has a market capitalization of $479.00 million and generates $111.75 million in revenue each year. The company earns $45.74 million in net income (profit) each year or $0.60 on an earnings per share basis. AC Immune employs 92 workers across the globe.

What is AC Immune's official website?

The official website for AC Immune is www.acimmune.com.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.